4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Background Predictive genetic screening of relatives of patients with hypertrophic
cardiomyopathy (HCM) caused by sarcomere protein (SP) gene mutations is current …

Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often
inherited primary cardiac disease, has now transformed into a contemporary highly treatable …

Hypertrophic cardiomyopathy (HCM) is a relatively common inherited myocardial disorder,
once regarded as largely untreatable with ominous prognosis and most visibly as a common …

Cardiomyopathies are a heterogeneous collection of diseases that have in common primary
functional and structural abnormalities of the heart muscle, often genetically determined. The …

Background: The impact of sex on phenotypic expression in hypertrophic cardiomyopathy
(HCM) has not been well characterized in genotyped cohorts. Methods: Retrospective cohort …

Abstract Purpose of Review We explore the sex-specific interaction of genetics and the
environment on the clinical course and outcomes of hypertrophic cardiomyopathy (HCM) …

Background PRKAG2 gene variants cause a syndrome characterized by cardiomyopathy,
conduction disease, and ventricular pre-excitation. Only a small number of cases have been …

Background: Pathogenic and likely pathogenic variants associated with arrhythmogenic
right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM), and hypertrophic …